What is Erste Group Bank's Forecast for BMY FY2026 Earnings?

Key Points

• Erste Group Bank marginally cut its FY2026 EPS estimate for Bristol Myers Squibb to $6.28 from $6.29, which is in line with the current consensus estimate of $6.28.
• Bristol Myers Squibb set FY2026 guidance of $6.05–$6.35 EPS and reported a Q1 beat with $1.58 EPS (vs. $1.46 est.) and $11.49 billion in revenue (vs. $10.85 billion est.).
• Wall Street sentiment is mixed—the stock’s average rating is a Hold with an average target price of $61.31, based on 8 Buys, 10 Holds and 1 Sell.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Stock analysts at Erste Group Bank cut their FY2026 earnings estimates for shares of Bristol Myers Squibb in a research note issued to investors on Monday, April 27th. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will post earnings per share of $6.28 for the year, down from their prior estimate of $6.29. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.28 per share.

Several other brokerages have also recently issued reports on BMY. UBS Group reaffirmed a "buy" rating and set a $70.00 target price on shares of Bristol Myers Squibb in a research report on Friday, March 6th. Royal Bank Of Canada began coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a "sector perform" rating and a $60.00 price objective on the stock. Barclays initiated coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an "overweight" rating and a $75.00 target price on the stock. Cantor Fitzgerald increased their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a "neutral" rating in a research report on Wednesday, April 8th. Finally, Bank of America lowered their price target on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a "buy" rating on the stock in a report on Thursday, April 9th. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $61.31.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $57.64 on Thursday. The firm has a market cap of $117.69 billion, a price-to-earnings ratio of 16.71, a PEG ratio of 0.17 and a beta of 0.27. Bristol Myers Squibb has a 52-week low of $42.52 and a 52-week high of $62.89. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The company's 50 day moving average is $59.55 and its 200 day moving average is $54.43.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.85 billion. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of large investors have recently modified their holdings of BMY. Gateway Investment Advisers LLC increased its holdings in Bristol Myers Squibb by 10.0% in the 3rd quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company's stock worth $5,117,000 after buying an additional 10,284 shares during the period. waypoint wealth counsel acquired a new stake in Bristol Myers Squibb during the 4th quarter valued at approximately $1,194,000. CWA Asset Management Group LLC lifted its stake in Bristol Myers Squibb by 25.9% during the 3rd quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company's stock valued at $6,781,000 after acquiring an additional 30,909 shares during the period. Stephens Inc. AR boosted its holdings in shares of Bristol Myers Squibb by 13.5% in the 3rd quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company's stock valued at $12,328,000 after acquiring an additional 32,476 shares during the last quarter. Finally, Railway Pension Investments Ltd increased its stake in shares of Bristol Myers Squibb by 3.7% in the third quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company's stock worth $51,396,000 after acquiring an additional 40,300 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the company's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares of the company's stock, valued at $9,820,824.16. This represents a 15.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.4%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb's payout ratio is 73.04%.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY’s raised 2026 revenue and adjusted EPS guidance and continued cost-cutting were cited as the main reasons for recent upward momentum; stronger guidance supports near-term earnings visibility and valuation upside. A Look At Bristol Myers Squibb (BMY) Valuation After Upbeat 2026 Guidance And Cost-Cutting Progress
• Positive Sentiment: Foundation Medicine expanded its CDx collaboration with BMS to develop an NGS-based companion diagnostic for MTAP homozygous deletions across indications — this deepens BMY’s precision oncology strategy and could improve trial enrollment and future targeted-therapy uptake if the drug candidate performs. Does BMS–Foundation Medicine’s MTAP CDx Partnership Expansion Change The Bull Case For Bristol-Myers Squibb (BMY)?
• Positive Sentiment: Erste Group nudged up FY2027 EPS estimates slightly (to $6.15), reflecting analyst confidence in BMY’s earnings trajectory; small upward estimate revisions can support multiple expansion if confirmed by results. Erste Group raises FY2027 EPS estimate for Bristol Myers Squibb
• Neutral Sentiment: BMY reports Q1 results tomorrow (pre-market) — the announcement is a near-term catalyst that could swing the stock based on growth-portfolio performance (Opdivo, Eliquis, late-stage assets) relative to guidance. Volatility is likely until results and management commentary are digested. Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q1 Results Tomorrow
• Neutral Sentiment: Coverage notes that Wall Street remains moderately optimistic despite BMY lagging the S&P over the last year — consensus is constructive but not unanimously bullish, so analyst commentary will matter around the print. Do Wall Street Analysts Like Bristol-Myers Squibb Stock?
• Neutral Sentiment: Industry reports (e.g., cryptococcosis market outlook) point to expanding infectious-disease markets, but these are broad trend items with limited immediate impact on BMY’s near-term stock movement. Cryptococcosis Drugs Market Outlook 2026-2036
• Negative Sentiment: Lilly’s $2.3B acquisition to strengthen its oncology pipeline underscores intensifying competition in oncology R&D; increased competitor M&A and pipeline investment can pressure market share or valuation if BMY’s pipeline doesn’t keep pace. LLY Expands Oncology Pipeline With $2.3B Ajax Therapeutics Acquisition

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.